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Abstract 15 
Anti-malarial drugs have long half-lives, so clinical trials to monitor their efficacy require long 16 
durations of follow-up to capture drug failure that may only become patent weeks after treatment. 17 
Reinfections often occur during follow-up so robust methods of distinguishing drug failures 18 
(recrudescence) from emerging new infections are needed to produce accurate failure rate 19 
estimates. “Molecular correction” aims to achieve this by comparing the genotypes between a 20 
patient’s pre-treatment (initial) blood sample and any infection that occurs during follow-up, 21 
‘matching’ genotypes indicating a drug failure. We use an in-silico approach to show that the widely 22 
used “match counting” method of molecular correction with microsatellite markers is likely to be 23 
highly unreliable and may lead to gross under- or over-estimates of true failure rates depending on 24 
the choice of matching criterion.  A Bayesian algorithm for molecular correction has been previously 25 
developed and utilized for analysis of in vivo efficacy trials. We validated this algorithm using in silico 26 
data and showed it had high specificity and generated accurate failure rate estimates. This 27 
conclusion was robust for multiple drugs, different levels of drug failure rate, different levels of 28 
transmission intensity in the study sites, and microsatellite genetic diversity. The Bayesian algorithm 29 
was inherently unable to accurately identify low-density recrudescence that occurred in a small 30 
number of patients, but this did not appear to compromise its utility as a highly effective molecular 31 
correction method for analysing microsatellite genotypes. Strong consideration should be given to 32 
using Bayesian methodology for obtaining accurate failure rate estimates during routine monitoring 33 
trials of antimalarial efficacy that use microsatellite markers.  34 
 35 
AAC Accepted Manuscript Posted Online 13 January 2020
Antimicrob. Agents Chemother. doi:10.1128/AAC.01517-19
This is a work of the U.S. Government and is not subject to copyright protection in the United States.
Foreign copyrights may apply.
 o
n
 January 16, 2020 at University of Liverpool Library
http://aac.asm
.org/
D
ow
nloaded from
 
Background  36 
 37 
Effective treatment of P. falciparum malaria infections is essential but is threatened by the spread of 38 
drug resistance to front-line antimalarial drugs, including artemisinin-based combination therapies 39 
(ACTs). Frequent monitoring of efficacy (1) is therefore necessary to confirm the effectiveness of 40 
current drugs, and to evaluate alternatives as they become available or necessary. The World Health 41 
Organization (WHO) recommends that endemic countries routinely re-test their currently used 42 
antimalarials at least every two years using standard patient-based in vivo trials. These are known as 43 
therapeutic efficacy study/studies  (TES)  (1); they generally only have one “arm” (i.e. the drug being 44 
evaluated). This terminology distinguishes TES from regulatory multi-arm trials used to evaluate 45 
proposed new regimens.  46 
 47 
Current first-line antimalarials are ACTs which are composed of an artemisinin derivative and a 48 
partner drug; the artemisinin component is short-lasting and rapidly clears parasites,  the partner 49 
drug has a longer half-life and is responsible for completely, but more slowly, clearing parasites. 50 
Ergo, if treatment fails due to resistance of parasites to the partner drugs, it may take several weeks  51 
for  these drug failures to become patent. TES must therefore follow-up patients for several weeks 52 
post treatment to ensure failures are detected. The consequence of this requirement for long 53 
follow-up periods in these TES  is that new infections not present at the time of treatment, termed 54 
“reinfections” (2) frequently occur during follow-up in moderate to high transmission areas. A 55 
patient presenting with detectable malaria parasites during follow-up (known as a recurrence / 56 
recurrent infection) may have a reinfection, which does not indicate that treatment failed to clear 57 
the patient’s initial infection. Thus,  recurrent infections  trigger molecular testing   that leads to 58 
them being classified as either: i) Plasmodium falciparum  clones that infected the patient pre-59 
treatment (initial clones) and were subsequently not cleared by treatment (termed recrudescence) 60 
or ii) reinfections  that occurred  during follow-up (3). In a methodology alternately called PCR 61 
correction or molecular correction, the genotype of the malaria infection at the time of treatment 62 
(the initial sample) is compared with the genotype of any recurrence during follow-up. The purpose 63 
of this comparison is to distinguish  recrudescences from reinfections such that patients with 64 
reinfections can be excluded from subsequent analysis, thus producing a “corrected” drug efficacy 65 
estimate. 66 
The original WHO and Medicines for Malaria Venture (MMV) consensus methodology was based on 67 
the use of length-polymorphic markers msp-1, msp-2, and glurp(3). An alternative system,  68 
microsatellite markers – segments of repeated genetic motifs -  has been explored (4-6), a proposed 69 
advantage being the lack of immune selection on ostensibly neutral microsatellite markers (7). In 70 
this methodology, researchers genotype microsatellite loci in both initial   and recurrent infections 71 
and count the number of matching loci in each patient i.e. the number of loci at which at least a 72 
single allele is shared between the initial and recurrent infection. They then define a certain number 73 
of matches to be indicative of recrudescence. In addition to their use in TES, microsatellites have 74 
also been commonly used to assess treatment failure in returning travellers in non-endemic areas 75 
(8-10). 76 
There are two inherent sources of bias in running TES, independent of the genotyping method: 77 
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a) A patient who fails to clear their initial infections may have a reinfection that becomes patent 78 
before the recrudescent clone reaches a detectable level; ethically, that patient must be treated 79 
and so is removed (or “censored”) from the study before the recrudescence can be observed.  80 
b) A patient who fails to clear their initial infection may have that infection persist at a low-lying 81 
level, below the limit of detection of light microscopy (assumed, see later, to be 108 total 82 
parasite count in the patient), such that parasites are never detected during follow-up; the 83 
frequency of this event   is influenced by the duration of follow-up in the trial i.e. the longer the 84 
follow-up, the less likely it is to occur.  85 
 86 
Classification of recurrences into reinfections and recrudescences also introduces potential bias into 87 
estimates of the true failure rate (11-14).  Genotyping of blood samples is imperfect and suffers from 88 
three key limitations. Firstly, patients are often infected by two or more malaria clones in high 89 
transmission areas and the lower density ”minority clones” contribute genetic signals that are hard 90 
to detect in the amplification process, meaning their low frequency alleles may fail to be detected in 91 
either blood sample (4). Secondly, there are inherent error rates when measuring the genotype of 92 
parasite, for example through imperfect determination of fragment length or sequencing error. 93 
Finally, there is the non-technical limitation that reinfections can, by chance, share alleles with 94 
clones of the initial infection – this is more pervasive in areas of lower genetic diversity (6).  These 95 
three factors combine to generate several additional several factors that need to be considered in 96 
the analysis of malaria drug trials: 97 
c) Recrudescent infections can be misclassified as reinfection if alleles of the recrudescent clone 98 
were  not detected when genotyping  the initial infection.  99 
d) Recrudescent infections can be misclassified as reinfection if a recrudescent clone has a 100 
sufficient number of base pair read errors (i.e., at multiple markers) such that it appears to be a 101 
reinfection.  102 
e)  A reinfection can be misclassified as recrudescent if it shares (by chance, or due to base pair 103 
read error) a genetic signal(s) with those clones present at time of treatment.  104 
Typically, microsatellite data are analysed by applying a mathematically simple match counting 105 
algorithm which  uses an arbitrary threshold for the number of loci that have common alleles 106 
between the initial and day of failure samples. In these algorithms, if the two samples have matching 107 
alleles at, or above, the threshold number of loci, they are classified as recrudescence, and 108 
otherwise, reinfections. Typically, classification of an infection as a recrudescence requires a match 109 
at most, if not all, sampled loci (4, 15, 16).  This kind of counting algorithm only deals with the 110 
unprocessed, “raw” genetic data and makes no allowance for errors  due to factors c to e described  111 
above resulting in  increased risk of misclassification, although more advanced statistical algorithms 112 
have been proposed to adjust for these potential biases (6). 113 
A recent publication (17) presented a statistical method based on  Bayesian probability to analyse 114 
microsatellite data to calculate drug failure rates. This method generates the posterior probability 115 
that a recurrent infection is a recrudescence and has subsequently been used to analyse TES data 116 
(18-20). The biases listed above mean that a simple method of counting matching microsatellites 117 
between samples may never be able to reliably classify a patient as reinfection or recrudescence. 118 
Bayesian analyses constitute a better, more flexible approach capable of dealing with these 119 
uncertainties and the advantages of a Bayesian approach are explained elsewhere (17).  120 
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We utilized a computer modelling approach to simulate therapeutic outcome following antimalarial 121 
therapy in anti-malarial trials. In these simulated data-sets, the parasitaemia of each patient’s clones 122 
is calculated at every time-step, thus  the true status (reinfection or recrudescence) of all recurrent 123 
infections is known. Using the simulated data, we then evaluated the ability of the Bayesian 124 
algorithm to correctly distinguish reinfections from recrudescences. This allowed us to quantify the 125 
accuracy of this method, which has not been possible in vivo; due to imperfect molecular correction 126 
techniques, the true failure rate of the population cannot be known.  We also compared the 127 
performance of the Bayesian algorithm to a threshold-based match counting algorithm, and 128 
investigated whether  the advantages of a Bayesian methodology are realised in the analysis of data 129 
from anti-malarial TES and whether this approach is truly as “robust” as postulated in the original 130 
paper (17). 131 
This study had three main objectives:  Firstly, to evaluate the accuracy of failure rate estimates 132 
generated using microsatellite data in conjunction with a match counting algorithm (as is currently 133 
typical). Secondly, to assess the advantages of Bayesian analysis methodology, both in its ability to 134 
recover the true failure rate and the diagnostic ability to distinguish recrudescence from 135 
reinfections. Thirdly, to check whether the methodologies based on microsatellite loci are robust 136 
across drugs with different post-treatment prophylactic profiles (i.e., partner drugs with varying half-137 
lives) which determine when reinfections start to occur, across different transmission intensities 138 
(which determine rates of reinfection in TES) and in regions with differing levels of genetic diversity 139 
at microsatellite loci.  140 
Methods 141 
Study Design 142 
We used existing pharmacokinetic / pharmacodynamic models (PK/PD) (21-23) to simulate parasite 143 
intra-host dynamics following treatment in 10,000 patients. We simulated whether original clones 144 
were cleared or survived drug treatment. If they  survived we then noted, whether the recrudescent 145 
clone(s) became patent during follow-up, and if/when reinfections occurred and became patent. We 146 
allowed clones present at time of treatment to have different numbers (densities) and assigned 147 
microsatellite alleles to each clone in the infection. This allowed us to simulate the genetic 148 
information that would occur during routine follow-up in these simulated patients that reflect the 149 
inherent problems in the follow-up and genotyping processes (i.e., inability to detect low density 150 
clones, and genotyping errors as described above). 151 
We ran 12 different scenarios, varying the drug, the failure rate, and the  level of transmission 152 
intensity, The latter factor is quantified as the force of infection (FO]) which is  the frequency at 153 
which reinfections emerge per person per year. Transmission intensity also affects  the initial 154 
number of clones in each patient at time of treatment (commonly known as the multiplicity of 155 
infection (MOI) or, equivalently, complexity of infection), and the level of genetic diversity in the 156 
population allele structure (details below). For each scenario, we used the Bayesian algorithm and 157 
the  match-counting algorithm to generate estimates of the failure rate. We then compared the 158 
estimate of the failure rate with the true failure rate to assess the accuracy of each algorithm. It is 159 
important to note that our methodology has two distinct steps: First, the mPK/PD model simulates 160 
parasite dynamics post-treatment, and we used a series of heuristics to calculate which alleles would 161 
be observable at any given time-steps. This provided data-sets that are akin to those obtained in 162 
vivo, where each patient’s infection is described by observable alleles in the initial sample and 163 
observable alleles of any recurrent sample. Secondly, we applied the match-counting and Bayesian 164 
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algorithms to this data to obtain failure rate estimates. The simulated data-set could then be used to 165 
analyse algorithm performance against the true failure rate (known from the simulation).  166 
Computational methodology 167 
All modelling and subsequent analysis was conducted using the statistical programming language R 168 
(version 3.5.1) (24). Figures were produced using base R graphics, and the ggplot2 package (25). For 169 
hardware details and programming considerations, see [Supplementary Information, SI].  170 
 171 
Trial Scenarios 172 
Twelve TES scenarios were simulated. The main body of this manuscript presents results obtained 173 
from simulations of artemether-lumefantrine (AR-LF) therapy, with results for the case of 174 
artesunate-mefloquine (AS-MQ) presented in the [SI]. The purpose of simulating two distinct 175 
treatments reflects the different post-treatment prophylactic duration of the drugs – AS-MQ persists 176 
at killing concentrations for longer than AR-LF. We primarily  wanted to analyse the use of 177 
microsatellite markers for AR-LF  treatment for which a Bayesian approach has been  previously 178 
been applied (17), but we also wanted to test if results were consistent for a drug with a longer post-179 
treatment prophylactic period.  For each drug, we simulated non-failing drugs with low failure rates 180 
(1-2%) and failing drugs with higher failure rate (~10%). True failure rate of the drug  is determined 181 
by the half maximal inhibitory concentration (IC50) of the drug in the parasite population; the IC50 182 
of each clone is drawn from a distribution of values (Table S1 of [SI]).  Note that we arbitrarily 183 
changed the mean IC50 value of partner drugs within the model to obtain different levels of 184 
treatment failure. We do not imply the values of IC50 here are representative of any particular field 185 
scenario, but rather use them to investigate the accuracy of techniques to analyse clinical trial data 186 
in a simulation environment. In our simulations, true failure rate changes with MOI (a higher MOI 187 
means that there are more clones within a patient that are potentially able to survive treatment, 188 
and so true failure rate increases), so we altered mean IC50 between scenarios for failing drugs to 189 
keep true failure rates within a percentage of each other between scenarios. Each drug calibration 190 
(i.e., non-failing AR-LF, failing AR-LF, non-failing AS-MQ and failing AS-MQ) were run in low, medium 191 
and high transmission settings.  These scenarios incorporated varying distributions of multiplicity of 192 
infection (MOI) at time of treatment, different frequency distributions of microsatellite alleles 193 
(obtained from Angola and based on transmission level, see parts 2.3 and 2.4 of [SI]), transmission 194 
intensity (quantified by FOI; see part 2.2 of [SI]) The calibration of each scenario in terms of MOI, 195 
allele frequency, FOI and mean IC50/True failure rate is presented in [SI]. Each scenario simulated 196 
10,000 patients for a 28-day follow-up period for AR-LF and as 42-day follow-up period for AS-MQ.  197 
The data we used for distributions of microsatellite markers came from three sentinel sites in Angola 198 
(17, 18), which represent areas with moderate to high transmission and thus relatively high diversity 199 
(Part 2.3 of [SI]). The risk of misclassifying a reinfection as a recrudescence is, intuitively, higher in 200 
areas of lower genetic diversity (potential error (e) described in the background), so we artificially 201 
generated an additional distribution of marker allele frequency with very low genetic diversity by 202 
modifying the allele distributions from the low diversity area (as described in part 2.4 of [SI] )to 203 
investigate the accuracy of failure rate estimates under this condition.   204 
 205 
PK/PD model specifications and output 206 
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We utilized a computer-based mechanistic PK/PD model of drug treatment of uncomplicated P. 207 
falciparum with either AR-LF or AS-MQ based on previous models (21-23). The methodology used 208 
the drug concentration profile in each patient to calculate the change in parasite counts 209 
(parasitaemia) of each malaria clone over time following drug treatment; this produced quantitative 210 
estimates of parasite dynamics in a patient following treatment (Figure S1, [SI]). The drug 211 
concentration over time in the patient population for each partner drug is shown in (Figures S2 and 212 
S3 [SI]). An alternative approach is to generate parasite dynamics by arbitrarily deciding on a day of 213 
recurrence for a patient, then assigning the recurrence as containing recrudescences and/or re-214 
infections (e.g.(26)). It would then be straightforward to draw the parasite numbers in each clone 215 
from a uniform distribution but a PK/PD model was chosen for the ability to easily test different 216 
levels of drug failure,  for increased realism, and to allow future users to easily re-calibrate this 217 
methodology with parameters of their choice. Pharmacokinetic parameters varied between patients 218 
and pharmacodynamic parameters varied between clones by drawing them from distributions of PK 219 
and PD parameters (Table S1 [SI]) for full parameter lists, and additional considerations.  220 
The number of initial clones in each patient was drawn from a distribution of multiplicity of infection 221 
(MOI) that depends on local transmission intensity (MOI ranges between 1 and 5; see Figure S4 of 222 
SI]; the starting parasitaemia of each clone was drawn from a log-uniform distribution between 1010 223 
and 1011. We describe parasitaemia in terms of parasite counts, rather than parasite densities. We 224 
do this because the models track changes in parasite counts over time and we do not parameterize 225 
patients in such a way that would allow us to easily convert counts to parasite densities (i.e., 226 
patients do not have parameters for blood volume, white blood cell (WBC) count or red blood cell 227 
count, etc.), nor would including these parameters aid the mechanistic simulation of the model or 228 
improve the accuracy of the results. For reference, assuming a patient with 4.5L of blood and a WBC 229 
count of 8,000/μl of blood, parasitaemia of 1010 and 1011  would correspond to densities of 2,222 230 
parasites/μl of blood and 22,222 parasites/μl of blood respectively, per WHO counting procedure 231 
(27). Previous modelling approaches used 1012 parasites as the upper limit of parasitaemia; this level 232 
of parasitaemia is likely to be lethal or at least exceed the maximum parasite density exclusion 233 
criteria in a clinical trial (typically 100,000 parasites /μl); hence we used 1011 as the upper limit for 234 
any single clone at the time of treatment. The number of reinfections that occurred during follow-up 235 
was determined by the parameter FOI which we used as our measure of transmission intensity 236 
(Section 2.2 of [SI]). The days on which reinfections occurred was drawn from a Poisson distribution 237 
whose mean was the FOI. Reinfections were assumed to emerge from the liver at a count of 105 238 
parasites (28, 29)  [SI]. PK parameters were varied between patients and PD parameters were varied 239 
between malaria clones such that each patient and clone responded differently to treatment (see 240 
[SI], Table S1 for table of PK/PD parameter means and associated coefficients of variation [CV]). The 241 
growth rate of each clone was assumed to be identical for every clone and set to 1.15/day as in 242 
previous modelling work (23, 30); this is equivalent to a parasite multiplications rate of 10  per 48 243 
hour cycle. The simulation assumed that if the total parasitaemia (i.e. the sum of parasitaemia of all 244 
clones) in a patient at any time, reached 1012, then density-dependent effects, such as fever, acted 245 
to control and stabilise the parasitaemia, effectively setting the growth rate of every clone in that 246 
patient to 0. Aside from this density-dependent effect, we did not attempt to model patient 247 
acquired immunity as accurately modelling this acquisition is notoriously difficult. It is likely to affect 248 
recrudescent and re-infecting clones equally such that we would not expect it to alter how recurrent 249 
infections are classified. We did not model parasite sequestration (see (31) for justification).  The 250 
output of this PK/PD model was, for each patient, the exact number of parasites of each malaria 251 
clone (be that clone an initial infection or a reinfection) at each time-step of the model (days); see 252 
figure S1 [SI] for an example. A patient in a real TES would be removed from the trial and re-treated 253 
 o
n
 January 16, 2020 at University of Liverpool Library
http://aac.asm
.org/
D
ow
nloaded from
 
when a recurrence occurred, but no such ethical imperative exists  in silico so we tracked the 254 
patients the full length of follow-up, with the advantage that we could determine if any initial clones 255 
were still present on the final day of follow-up, even though, in vivo, that patient may have been 256 
removed from the trial (right-censored) earlier due to a recurrence caused by reinfection.  257 
 258 
Modelling microsatellite genotyping and detectability of alleles 259 
Genotypes were assigned to every clone (both initial and reinfections) at seven microsatellite 260 
markers: 313, 383, TA1, polya, PfPK2, 2490 and TA109; alleles at each marker were defined by their 261 
length (base pairs), see details in part 2.3 of  [SI].   262 
The genotype of the initial malaria infection of each patient was taken on the day of treatment. This 263 
genotype signal is a composite of all the clone(s) present in the initial infection and is determined by 264 
the technical accuracy and sensitivity of genotyping (points (b) and (c) in the Background and see 265 
later). Each patient was then checked for recurrent parasites on days of follow-up in a typical clinical 266 
trial schedule i.e. day 3, 7, 14, 21 and 28 for AR-LF and additional days 35 and 42 for AS-MQ.  267 
On all days of follow-up except day 3, a recurrence was identified if the sum parasitaemia of all 268 
clones in a patient exceeded 108 which we assumed was the minimum parasitaemia at which 269 
detection by light microscopy was possible (32).  This corresponds to a parasite density of roughly 22 270 
parasites/μl of blood assuming a patient with 4.5L of blood and 8,000 WBC/μl. If total parasitaemia 271 
was less than 108 then recurrent parasites would not be observed by microscopy (and thus, the 272 
patient would not be genotyped on that day). On day 3, if total parasitaemia exceeded 108 but was 273 
<25% of the total parasitaemia on the initial sample, the patient continued in the trial; if parasites 274 
were present at >25% of initial parasitaemia, that patient was classed as an early treatment failure,  275 
per WHO procedure (1);. Genotyping of initial and recurrent samples was then simulated using the 276 
following 3-stage protocol: 277 
Firstly, we included a “sampling” limit: A finite volume of blood is available for genotyping. A 278 
parasite clone would not be detected if its density were so low that no parasites were included in 279 
the blood sample analysed.  Thus, the density and volume of the processed blood sample defined 280 
the limit of detection. We assumed this limit to be 108 (i.e., no clone present in less than 108 281 
parasites would be detected); see part 3 of [SI] for calculation and justification.  282 
Secondly, the “majority” allele for each microsatellite is the allele with the highest parasitaemia (if 283 
multiple clones share alleles at a marker, the allelic signal for that marker is the sum of parasitaemia 284 
of the clones). We assumed that for an allele to be detected, the parasitaemia of that allele must be 285 
≥25% of the parasitaemia of the majority allele; this reflects the sensitivity of microsatellite 286 
genotyping to infer low-frequency alleles.  287 
Finally, we included the chance that the length of each microsatellite may be mis-read due to 288 
genotyping errors such as stutter bands (7) . The chance of an  error of +/- length x was assumed to 289 
be described by the geometric distribution 0.8 * (0.2)
x
 , described in (17).  290 
The output of these simulations was, for each patient, the microsatellite alleles (quantified by their 291 
length in base-pairs for each loci) at each of the seven loci, observed in the initial sample, and at any 292 
recurrent infection in that patient. A small example (100 patients) is shown in [Supplementary file 1] 293 
This is exactly the data recorded in standard TESs (and is the input used for the Bayesian algorithm in 294 
vivo as in (17, 18)) so this data  formed the basis for our PCR-correction and failure rate estimates. 295 
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Terminology of results 296 
Our terms “Recurrent infection/Recurrence”, “Recrudescence” and “Reinfection” are consistent with 297 
the WHO terminology (2).   298 
We frequently use the additional term “true failure” to describe the failure rate that we know 299 
occurred during our simulations (and which is unknown in a real TES).  We determined whether each 300 
patient was a “true failure” based on parasitaemia: A patient was a true failure if, on the final day of 301 
follow-up (day 28 for AR-LF, day 42 for AS-MQ), they still harboured any parasites from any initial 302 
clone. The true failure rate is the frequency of these patients across the entire population. Our 303 
model tracked patients over the full length of follow-up, thus our “true failure” classification 304 
captured patients who would, in a real trial, have been removed earlier in the trial with a recurrent 305 
infection classified as a reinfection (and whose recrudescent clones would not then be observed).  306 
A key advantage of our in silico approach is its ability to interrogate the Bayesian algorithm; i.e., 307 
investigate diagnostic ability and determine in which circumstances it would misclassify recurrences. 308 
For these analyses, we separated true failures into ‘high’ and ‘low’ density recrudescence. The 309 
performance of PCR correction is likely to depend on its ability to detect genetic signals from low-310 
density clones. The detection limit for low-level genetic signals in our simulation was 25% (to reflect 311 
current genotyping sensitivities, described above) so its is useful to compare the methodologies 312 
when patients have high-density recrudesce (recrudescing clones are present at >25% in both initial 313 
and recurrent samples) and low-density clones. Technically, a high density recrudescence was 314 
defined as occurring when three conditions were met: (i) if there is a mixed infection of new and 315 
recrudescent clones on the day of recurrence, recrudescent clones must be >25% of the total 316 
infection (more specifically, the sum parasitaemia of all recrudescent clones on the day of 317 
recurrence must be >25% the sum parasitaemia of all clones on the day of recurrence)) and (ii), 318 
Clones that recrudesce must constitute at least 25% of the initial infection (more specifically, the 319 
sum parasitaemia of all recrudescent clones on the day of recurrence must have been  >25% of the 320 
total parasitaemia of all clones in the initial sample). )  (iii) the total number of parasites in 321 
recrudescing clones on the day of recurrence must be ≥108 (to be consistent with the sampling limit 322 
defined above).  If any one of these conditions is not met then the failure is defined as “low density”.  323 
In this manner, we determined the true classification of each recurrence as a reinfection, high 324 
density recrudescence or low density recrudescence. 325 
Match counting algorithm 326 
A match counting algorithm compared the number of microsatellite loci that have at least a single 327 
allele shared between the initial and recurrent sample (termed a “matching” loci). Typically, use of 328 
microsatellite markers in vivo  requires a high number of matching loci to classify an infection as 329 
recrudescent (either all loci, or permitting a single locus not to match, i.e.: (4, 15, 16)). Herein, with 330 
the 7 loci modelled, we vary the threshold number of matching loci required to classify a 331 
recrudescence to determine the impact of this choice of threshold on failure rate estimates.  This is a 332 
counting algorithm where a recurrent infection is defined as a recrudescence when the number of 333 
matching loci is greater than or equal to a specified threshold. Six threshold values were analysed for 334 
this method: 2, 3, 4, 5, 6 and 7 matching loci (e.g. if a recurrent infection had 3 matching loci with 335 
the initial infection, that recurrence was classified as a recrudescence with a threshold of 2 or 3 loci, 336 
but as a reinfection with the other thresholds.  337 
Bayesian analysis method 338 
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We used the Bayesian analysis method described in (17) to interpret our simulated results and 339 
obtain posterior probabilities of recrudescence for each patient. In brief, the Bayesian algorithm 340 
uses a Markov chain Monte Carlo approach to sample from the posterior probability of 341 
recrudescence for each sample, with the ratio of likelihoods of a reinfection versus a recrudescence 342 
derived from the frequencies of the observed alleles. The algorithm jointly estimates several key 343 
parameters, such as the genotyping error rate, and accounts for missing data by sampling hidden 344 
alleles.  The data input into the Bayesian algorithm in our simulations is the same as occurs in 345 
analysis of in vivo trial data, i.e., the microsatellite profile of initial and recurrent infections in each 346 
patient as shown in [Supplementary file 1].  347 
The Bayesian analysis was then used to define a recurrence as being a recrudescence when posterior 348 
probability of recrudescence in that patient exceeded a value p, where p lies between 0 and 1.  349 
Note that the Bayesian algorithm is applied to our simulated data-sets in the same way it is applied 350 
to in vivo data (described in (17)). Crucially, this means that the priors for all parameters are 351 
uninformative – we are not calculating any given parameter in the mPK/PD framework and then 352 
using that parameter as a prior for the Bayesian algorithm (which would clearly invalidate results). 353 
Note, though, that posterior estimates from (17) are used to inform the chance of allele length being 354 
mis-read in the mPK/PD model, described above.  355 
Assessment of algorithm accuracy 356 
Both the match-counting algorithm and Bayesian analysis classified a recurrent infection as either 357 
reinfection or recrudescence depending on the choice of threshold (for the match counting 358 
algorithm) or posterior probability  p (for the Bayesian analysis). These classifications were then used 359 
to generate failure rate estimates for the simulated TES  using survival analysis (the WHO-360 
recommended method (1)) with the R packages survival (33) and survminer (34) . The failure 361 
estimates for both methods were then compared with the true failure rate to assess their accuracy.  362 
The distribution of the posterior probability of recrudescence calculated using the Bayesian 363 
algorithm was plotted for each scenario, with recurrences stratified into their true status: low-364 
density recrudescence, high-density recrudescence or reinfection. Receiver operator characteristic 365 
(ROC) curves were constructed using the posterior probability at which an infection would be 366 
classified as a recrudescence (from 0 to 1). The area under the ROC curve (AUC)  was used to 367 
quantify the diagnostic ability of the method (35), with an AUC of >0.8 considered to be a “good” 368 
test and an AUC of >0.9 considered to be an “excellent” test.  369 
We evaluated the ability of the Bayesian algorithm to detect low-density recrudescence, by 370 
calculating the posterior probability of recrudescence estimated by the Bayesian algorithm for each 371 
recurrent infection and categorizing each infection  as reinfection, low-density recrudescence or 372 
high-density recrudescence as described above.  373 
Results  374 
Results were generated for AR-LF and AS-MQ under the assumption of a failing and non-failing drug 375 
for three scenarios of transmission intensity (methods). Here we focus on the results for AR-LF while 376 
the results for AS-MQ are fully described in [SI].  377 
Failure rate estimates and comparison to true failure rate.  378 
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The  match counting algorithm was sensitive to transmission intensity; no threshold value of 379 
matching loci at which a recurrence was classified as recrudescent was able to accurately estimate 380 
true failure rate across all transmission scenarios for either failing (Figure 1) or non-failing (Figure 2) 381 
AR-LF. Failure rate estimates declined as the threshold  increased. Failure rate estimates increased 382 
as transmission increased, presumably due to the greater number of reinfections, some of which will 383 
be misclassified as recrudescences; this effect was greater at low thresholds when the probability of 384 
such misclassification was greater. A threshold of 4 matching loci produced estimates close to the 385 
true failure rate for all non-failing AR-LF scenarios. For failing AR-LF scenarios, a threshold of 3 386 
matching loci produced the closest estimate to true failure in the low transmission scenario, and a 387 
threshold of 4 matching loci produced the closest estimate in the high transmission scenario, with 388 
the medium transmission scenario intermediate between the two. However, using a threshold of 3 389 
matching loci in a high transmission scenario over-estimated failure rate (estimated failure rate of 390 
0.18 compared to a true failure rate of 0.1). A threshold of 4 matching loci gave an estimate of 0.08 391 
relative to a 0.0997 true failure rate for the failing, medium transmission scenario and an estimate of 392 
0.077 relative to a true failure rate of 0.0965 for the failing, low transmission scenario. A threshold of 393 
7 matching loci resulted in extremely large under-estimates of failure rates for failing AR-LF: 0.005 394 
relative to true failure rate of 0.0965 in the low transmission scenario, 0.008 relative to true failure 395 
of 0.0997 in the medium transmission scenario and 0.006 relative to true failure rate of 0.1 in the 396 
high transmission scenario.  397 
In contrast to the match-counting method, the Bayesian algorithm recovered true failure rate to a 398 
high degree of accuracy across all transmission settings and for both calibrations of true drug failure 399 
rate (Figure 1 and Figure 2). Values of the posterior probability of recrudescence, p, used to 400 
distinguish recrudescence from reinfection between 0.1 and 0.9 produced good, consistent failure 401 
rates estimates with only a slight decline as p increased; using p = 1 to classify a recrudescence 402 
resulted in a substantial decrease in failure rate estimates. For all non-failing and failing drug 403 
scenarios, treating all infections with p ≥ 0.1 as recrudescence generated a failure rate estimate 404 
within 0.01 of the true failure rate. 405 
Receiver Operator Characteristic (ROC) curves for the Bayesian algorithm. 406 
The general trend was that the AUC of the ROC curve decreased as transmission intensity increased 407 
(Figure 3), with values of 0.872 and 0.835 in the failing and non-failing high transmission scenarios 408 
respectively – these correspond to a “good” diagnostic test. AUC was higher for any given 409 
transmission scenario in failing AR-LF than non-failing AR-LF. When the ROC curve was calculated for 410 
only high-density recrudescence AUC increased to ≥0.968 in all scenarios – an “excellent” diagnostic 411 
test.  412 
Distribution of posterior probability of recrudescence 413 
Figure 4 shows the distribution of the posterior probabilities of recrudescence for all recurrences, 414 
stratified according to the true classification of their recurrence: Reinfection, low-density 415 
recrudescence, or high-density recrudescence. The distributions were nearly binary in every 416 
scenario: Nearly all posterior probabilities in the patient population were <0.1 or≥0.9. Some trends 417 
here were intuitive (note different scales on the Y axes) : i.e., larger number of reinfections occurred 418 
as transmission intensity increased and larger number of recrudescences occurred in scenarios in 419 
which  failing drugs were administered. The small number of patients whose infections had 420 
estimated probabilities of recrudescence between (but not including) 0.1 and 0.9 was reflected in 421 
the minor changes in failure rate estimates as p changed in Figure 1 and Figure 2.  422 
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Most patients whose recurrence had   p <0.1 were reinfections. Given that ≥0.1 was the choice of p 423 
that produces the most accurate failure rate estimate (Figure 1 and Figure 2), the cause of the 424 
(slight) under-estimate of failure rate was due to the proportion of patients with infections at p <0.1  425 
who had, in reality, recrudescent infections. In simulations of failing drugs, at all transmission 426 
intensities, ~5% of recurrent infections that had p <0.1 were truly recrudescent infections . For 427 
simulations of non-failing drugs, at all transmission intensities , ~2.5% of recurrent infections that 428 
had p <0.1were truly recrudescent infections. Notably most of these were low density 429 
recrudescence; only 0.03%-0.05%  of recurrent infections that had p <0.1 were high-density 430 
recrudescences  in simulations of failing drugs, and 0.02%-0.06% of recurrent infections that had p 431 
<0.1 were high-density recrudescences in simulations of non-failing drugs . There were a small 432 
number of recurrent infections with p ≥0.1 which were truly reinfections but in all scenarios this 433 
number was small relative to the number of recurrent infections that had  p <0.1 and were truly 434 
recrudescent.  435 
Consequently, the under-estimation of failure rate that occurs due to truly recrudescent infections 436 
having p <0.1 was greater than the over-estimation due to reinfections having p ≥0.1; thus these 437 
reinfections with p ≥0.1 were not leading to an over-estimation of failure rate.  438 
Figure 1, Figure 2 and Figure 4 show that over-estimation of failure rate due to misclassification of 439 
reinfection as recrudescence did not significantly affect the Bayesian algorithm due to its high 440 
specificity; nearly all reinfections have a posterior probability of recrudescence of <0.1. A slight-441 
under-estimate of failure rate occurred with all values of p ≥0.1-≥0.9 inclusive to classify a 442 
recrudescence, due to the algorithm assigning posterior probabilities of <0.1 to a small proportion of 443 
infections with low density recrudescence.   444 
Determinants of posterior probability of recrudescence 445 
Figure 5 is a contour plot showing the estimated posterior probabilities of recrudescence estimated 446 
by the Bayesian algorithm as a function of the densities of the recrudescent clone(s) in the recurrent 447 
and initial sample. There was a clear trend of the posterior probability of recrudescence increasing 448 
as both densities increase, reinforcing the result illustrated in Figure 4: the density of recrudescent 449 
clones was an important determinant of the posterior probability of recrudescence returned for a 450 
given patient. Errors in classification were due almost entirely to the finite sensitivity of genotyping 451 
causing some low-density clones to be missed during genotyping. 452 
 453 
Analysis of Artesunate-Mefloquine  454 
We simulated and analysed AS-MQ in the same manner as for AR-LF. Full results are shown in [SI]. 455 
Results were very consistent with those of AR-LF: The match counting algorithm for classifying 456 
recurrences as reinfection or recrudescence could not consistently provide accurate  failure rate 457 
estimates across a variety of scenarios and often resulted in extreme over or under-estimates of true 458 
failure rate, depending on the choice of threshold. The Bayesian analysis method generated failure 459 
rate estimates to a high degree of accuracy across all scenarios, although there was an under-460 
estimate of 1.6 percentage units in the high transmission, failing drug scenario. As with AR-LF, using  461 
p ≥ 0.1 to classify an infection as a recrudescence provided the most accurate failure rate estimate 462 
for AS-MQ in every scenario.  463 
Very low genetic diversity scenario  464 
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As expected, in the very low genetic diversity scenarios, failure rate estimates increased due to 465 
misclassification of reinfection as recrudescence (factor I) identified in the Background) [SI]. The 466 
match counting algorithm was unable to recover accurate failure rate estimates in any scenario. 467 
However, using a high threshold of matching loci to classify a recrudescence (6 or 7) did not lead to 468 
over-estimates of failure rate, even in a high transmission setting, under conditions of very low 469 
genetic diversity. Importantly, the Bayesian method recovered accurate failure rate estimates in  low 470 
genetic diversity  scenarios when using p ≥ 0.1 to classify a recrudescence [SI].  471 
Patients with sub-patent, undetectable parasitaemia during follow-up 472 
We calculated the number of patients who had undetectable, sub-patent parasitaemia on the final 473 
day of follow-up (i.e. a total <108  parasites, either reinfection or recrudescence), and the proportion 474 
of these patients who were harbouring sub-patent recrudescent infections. These results are shown 475 
in full in Table S3 of [SI]. The results we present above are based on analysis of patients with patent 476 
recurrent infections (i.e. those who have detectable parasites during follow-up). In our model, it is  477 
possible for a patient to be a true failure (i.e., fail to clear their initial parasite clones), but never 478 
have detectable levels of parasites (either recrudescent clones or reinfections), during follow-up 479 
(methods). If the number of these patients were large, it would induce bias in our results. However, 480 
the proportion total patients who were true failures but had no recurrent infection was extremely 481 
low (between 0 and 0.001 across all scenarios for non-failing and failing AR-LF), so we can assume 482 
duration of follow-up, at least in our simulations, was sufficiently long to capture nearly all failures 483 
and hence safely draw conclusions about the entire study population.  484 
 485 
Discussion 486 
Our in silico experiment showed that the Bayesian algorithm generated extremely accurate 487 
estimates of true failure rate across different transmission intensity and drug failure rate scenarios. 488 
In contrast, the match counting algorithm showed high potential for misclassification bias, with no 489 
single threshold able to consistently estimate the true failure rate.  490 
Our results highlight the important role that computer modelling approaches can play in evaluating 491 
the performance of genotyping-based classification algorithms. This kind of approach is essential for 492 
this evaluation because, unlike real field data, we know the true failure rate of drugs in silico so can 493 
readily identify the most accurate and/or robust method of analysis. In contrast, analysis of field 494 
data demonstrates that failure rate estimates vary depending on choice of methodology (e.g., 495 
between criteria used to define recurrence as reinfection or recrudescence, i.e. (11)) but, since the 496 
real failure rate in a clinical trial is unknown, it is not possible to demonstrate which  method is most 497 
accurate or robust. A further advantage of simulated datasets is that we can observe the conditions 498 
under which a method fails to return a correct classification (for example,  Figure 4). We are 499 
confident in our conclusions for several reasons.  500 
Our first main conclusion is that despite its wide use, match counting of microsatellites for 501 
distinguishing recrudescence from reinfection is not a robust approach  because the estimated drug 502 
failure rate is   highly dependent on the threshold used to define a recrudescence. By definition the 503 
same clone of malaria will have the same genotype between the initial and recurrent sample. 504 
However, the observed genotype (described by the microsatellite alleles) may differ due to issues 505 
inherent in the genotyping method (failure to detect minority alleles or errors in measuring base-506 
pair length of alleles) – accounting for this difference is the purpose of including a degree of 507 
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flexibility in the molecular correction process i.e., varying thresholds.  Use of microsatellites to 508 
correct trials in vivo has, up to this day, generally relied upon a simplified analysis method such as 509 
the match counting algorithm described here. Hwang et al. (16) used 8 markers and defined a match 510 
at 7 or more loci to be a recrudescence. Greenhouse et al. (4) investigated 6 markers, and 511 
subsequently used 4 to analyse samples, with a match at every locus being required to classify a 512 
recurrence as  a recrudescence. Mwangi et al. (15) used 5 loci and considered a match at 5 to be a 513 
recrudescence, 0 to be a reinfection, and intermediary values to be mixed infections. 514 
The high thresholds generally used to classify a recurrence as a recrudescence (either most, or all, of 515 
the available loci must match to define a recrudescence) likely results in substantial under-estimate 516 
of failure rate. For the in silico failing AR-LF results presented here, failure rate estimates with a 517 
threshold of 2 ranged between 15% in a low transmission scenario to 50% in a high transmission 518 
scenario, relative to true failure rates of ~10% (Figure 1). However, a threshold of 7 provided 519 
estimates that ranged between 0.5% and 0.6% relative to true failure rates of ~10% . For non-failing 520 
AR-LF (Figure 2) failure rate estimates with a threshold of 2 ranged from 7% in a low transmission 521 
scenario to 24% in a high transmission scenario, relative to true failure rates of ~2%. In other words, 522 
the potential bias induced by choice of a break-point for the match counting algorithm could result 523 
in either rejecting an efficacious drug or continuing to use a failing drug and this is further 524 
complicated by the sensitivity of the break-point to transmission intensity (Figure 1 and Figure 2); 525 
the same issues are present in using the match counting algorithm for AS-MQ [SI]. This is perhaps 526 
not surprising: In the context of genetic markers for classification of recurrent infections in TES, 527 
microsatellites are very similar to the marker glurp used in the WHO/MMV method i.e. are defined 528 
only as length polymorphism with no allelic families. This has led some commentators to suggest 529 
glurp is so unreliable that it should simply be omitted from the WHO/MMV method or used only to 530 
resolve disparate msp-1 and msp-2 results (11).   531 
The results presented here strongly suggest that stringent thresholds (i.e., requiring all or most loci 532 
to have matching alleles) will under -estimate failure rate (and over-estimate efficacy). With the 533 
seven microsatellites used in these simulations, failure rate estimates produced by the match 534 
counting algorithm varied with both the choice of threshold and the transmission intensity but in all 535 
scenarios a threshold of 5 matching loci under-estimated failure rate; either 3 or 4 produced the 536 
closest estimate (Figure 1 and Figure 2). A threshold of 2 would lead to large over-estimates of 537 
failure rate. The reason that stringent thresholds under-estimated failure rate is because low-density 538 
recrudescence can be overlooked in patients who have a polyclonal initial or recurrent infection. 539 
Note that the threshold producing the most accurate estimate increased from 3 to 4 as transmission 540 
increased from low to high – this is because in higher transmission areas there was a greater impact 541 
of reinfections incorrectly classified as recrudescence due to sharing alleles by chance.   However, 542 
this will be dependent on the genetic diversity of the markers used. 543 
When a match counting algorithm for interpreting microsatellite data is  used, we strongly suggest 544 
that  failure rates obtained with multiple thresholds  points are reported, (for example Plucinski et 545 
al. reported failure rate estimates based on thresholds of matching at all loci and matching at all 546 
except a single loci; their table 2). This reflects the difficulty (in our opinions, the impossibility) of 547 
identifying a robust threshold (our figures 1 and 2) a priori. Additionally, we suggest that stringent 548 
thresholds (requiring all or a very high proportion of loci to be matching) are generally avoided.  549 
Inaccuracies of failure rate estimates using the match counting algorithm were a concern for failing 550 
drugs; a threshold of 4 was a reasonable approach in our  non-failing drug scenarios as most 551 
recurrences were likely to be reinfection and 4 appeared to be a sufficient threshold to prevent 552 
over-estimation of failure rates due to misclassifying reinfections as recrudescence. Consequently, a 553 
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feasible approach for using microsatellites in TES would be to use the match counting algorithm 554 
initially, assess the failure rate estimates produced with a range of thresholds  and pass any result 555 
that indicates a drug failure rate of higher than 5% through a Bayesian algorithm for re-analysis. We 556 
note that in our results,  the estimates produced by each threshold are sensitive to transmission 557 
intensity, but even in a high transmission intensity, a threshold of 4 would  not mistakenly indicate 558 
that a failing drug was non-failing (Figure 1).   559 
Our second main conclusion is that application of the Bayesian algorithm produces relatively 560 
accurate and stable estimates of failure rate in all transmission scenarios for both failing and non-561 
failing with use of a posterior probability p of 0.1. This result is consistent for analysis of AR-LF, AS-562 
MQ and even for AR-LF in a very low genetic diversity setting, where a p of 0.1 is effective due to the 563 
high specificity of the Bayesian algorithm, i.e., misclassification of reinfection as recrudescence is 564 
extremely infrequent (Figure 4 and [SI]). However, note that in the very low diversity setting, failure 565 
rate estimates increased as transmission intensity increased, and in areas of higher transmission 566 
than we simulated here there may be a risk to accurate classification with this method; though this 567 
pre-supposes that low genetic diversity (characteristic of low-transmission settings) could occur 568 
within an area of high transmission.      569 
The type of PK/PD modelling that we used to generate parasite dynamics post-treatment has been 570 
widely validated and used by our group (e.g. (21, 22)) and the approach is being increasingly used by 571 
other groups (e.g. (36)). Results are highly robust for both AR-LF and AS-MQ (i.e., partner drugs with 572 
different lengths of post-treatment prophylaxis), different levels of transmission intensity, and 573 
different levels of drug failures and return an intuitive result (increased failure rate) when very low 574 
genetic diversity is simulated. We wish to underline the fact that there are a large number of PK/PD 575 
calibrations for AR-LF and AS-MQ in the field; we have chosen the parameterizations here [SI] based 576 
on our previous work and  because their role in the current study is solely to generate plausible 577 
profiles of parasite dynamics over time (i.e., figure 1 of (37)) and obtain genetic data with which we 578 
can evaluate different methods of molecular correction. We could describe parasite dynamics using 579 
other methods (for example, pre-determining a number of clones at a given time and randomly 580 
drawing their densities, e.g. (38)) but chose to use a PK/PD model for increased realism, relative 581 
simplicity, and to provide the ability for ourselves or other users to calibrate the model to their 582 
liking. The crucial part of our methodology is how we calculate detection of microsatellites in blood 583 
samples; specifically that it is based on the relative density of  alleles in the parasitaemia (and thus 584 
dependant on relative clone numbers) and accounts for a “sampling limit” and inherent errors in 585 
reading microsatellite lengths. We are confident that while use of different PK/PD parameters would 586 
change a given patient’s parasite dynamic profile, anything but the most novel parameterization 587 
would be unlikely to sufficiently change our results given that a) we simulate 10,000 patients and b) 588 
parameters are varied within the model such that a large range of alternative parameterization is 589 
already at least partly included in our simulations.  590 
The main practical drawback of the Bayesian algorithm is the need to run a Bayesian analysis. The 591 
methodology is published and available (17) but application requires some experience in 592 
programming and Bayesian statistics. The analysis is computationally expensive (see [SI]) and may be 593 
difficult to run on an average personal computer. However, this should not be allowed to be an 594 
impediment, given the importance of accurate malaria drug trials, and one solution to this would be 595 
for a central body to offer such analyses as a service, or to support application of the algorithm 596 
through an internet-based application.   597 
One problem with the microsatellite genotyping approach  is its inability to detect low density 598 
“minority” clones (the limit here was set to 25%), a problem common to other markers such as the 599 
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WHO markers msp-1, msp-2, glurp (the peak height cut-off for ignoring a signal as noise is generally 600 
between 10-20% (11)); the slight under-estimates of failure rate produced by Bayesian analyses 601 
occurred primarily because the algorithm is unable to correctly identify all low-density 602 
recrudescence (Figure 4 and 5) – this reflected minority alleles being missed during  amplification 603 
and sequencing. There is now considerable interest in using deep-sequenced amplicons as markers, 604 
because this method allows detection of alleles at very low frequencies (less than 2% of the 605 
frequency of the most frequent allele). We are currently investigating these markers, using a 606 
strategy analogous to that described above, to investigate their potential role in molecular 607 
correction. Even if they prove accurate and robust, it is likely to be several years before they are 608 
validated, a consensus methodology identified and routinely used in trials.  Meanwhile it appears 609 
that Bayesian analysis of a suite of microsatellite markers does constitute a robust and accurate 610 
method for analysis of malaria drug efficacy trials  611 
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 782 
FIGURES  783 
 784 
Figure 1: Failure rate estimates obtained using  the  match counting algorithm and the Bayesian analysis algorithm for  failing AR-LF under low, medium and high 785 
transmission scenarios. The true failure rate is denoted in each plot by the horizontal grey line. For the match counting algorithm, the  threshold for the number of 786 
matching loci at which a recurrence is classified as a recrudescence varies between  2 and 7.  For the Bayesian analysis, the cut-off for posterior probability at which a 787 
recurrence is classified as a recrudescence varies between ≥0.1 and ≥0.9.  788 
Figure 2: Failure rate estimates obtained using the match counting  algorithm and the Bayesian analysis algorithm for non-failing AR-LF under low, medium and high 789 
transmission scenarios. The true failure rate is denoted in each plot by the horizontal grey line. For the match counting algorithm, the  threshold for the number of matches 790 
at which a recurrence is classified as a recrudescence varies between  2 and 7.  For the Bayesian analysis, the cut-off for posterior probability at which a recurrence is 791 
classified as a recrudescence varies between ≥0.1 and ≥0.9.  792 
Figure 3: Receiver operator characteristic (ROC) curves showing diagnostic ability of the Bayesian analysis method for 3 scenarios of transmission intensity for non-failing 793 
and failing artemether-lumefantrine (AR-LF). ROC curves and area under the roc curve (AUC) are shown for all recrudescence and for high density recrudescence. A high 794 
density recrudescence was defined as explained in the main text.  795 
Figure 4: Distribution of the posterior probabilities of recrudescence estimated  by the Bayesian algorithm for 3 scenarios of transmission intensity for non-failing and failing 796 
artemether-lumefantrine (AR-LF). A high density recrudescence was defined as explained in the main text.  797 
Figure 5:  Contour plot of the posterior probability of recrudescence estimated by Bayesian algorithm as a function of the density of recrudescent clones (i.e., the 798 
proportion of the recrudescent clones in the total recurrent infection biomass) in the initial sample and the recurrent sample. This plot is the combined data of all 6 799 
scenarios modelled for artemether-lumefantrine (AR-LF). Each contour line indicates the posterior probability of recrudescence and the area between the lines the number 800 
of recurrent infections in the population with those posterior probabilities.  801 
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